Osimertinib trials for Non-Small-Cell Lung Cancer

All Osimertinib trials · All Non-Small-Cell Lung Cancer trials

Phase breakdown

Recruiting trials studying Osimertinib for Non-Small-Cell Lung Cancer

• A Study of BL-B01D1 in Combination With Osimertinib Versus Osimertinib as First-Line Treatment in Patients With EGFR-Mutated Locally Advanced or Metastatic Non-Small Cell Lung Cancer(PANKU-Lung04)
  NCT06838273 · Phase: Phase 3 · Ages: 18 Years and older · Sex: All (male and female) · 1 location
• A Study of BL-B01D1 in Combination With Osimertinib as Perioperative Therapy in Patients With EGFR-mutated Resectable Non-small Cell Lung Cancer(PANKU-Lung09)
  NCT07642024 · Phase: Phase 2, Phase 3 · Ages: 18 Years to 75 Years · Sex: All (male and female) · 2 locations
• A Study of Ivonescimab in Combination With Dato-DXd or Osimertinib in People With Non-Small Cell Lung Cancer
  NCT07535437 · Phase: Phase 1, Phase 2 · Ages: 18 Years and older · Sex: All (male and female) · 7 locations
• A Study of SKB571 Combination Therapy in Participants With Non-Small Cell Lung Cancer (NSCLC)
  NCT07622186 · Phase: Phase 2 · Ages: 18 Years to 75 Years · Sex: All (male and female) · 27 locations
• A Study to Assess Adverse Events and Change in Disease Activity of Intravenous (IV) Telisotuzumab Adizutecan, Monotherapy or in Combination With Osimertinib, Compared to Standard of Care in Adult Participants With Locally Advanced or Metastatic EGFR-Mutated Non-Squamous Non-Small Cell Lung Cancer
  NCT07155187 · Phase: Phase 2, Phase 3 · Ages: 18 Years and older · Sex: All (male and female) · 110 locations
• A ctDNA-guided Phase II Trial of Osimertinib in Combination With Sacituzumab Tirumotecan in EGFR-mutated Advanced NSCLC Patients With Positive ctDNA After lead-in Osimertinib Monotherapy
  NCT07375316 · Phase: Phase 2 · Ages: 18 Years and older · Sex: All (male and female) · 4 locations
• Clinical Trial Evaluating the Safety, Tolerability and Preliminary Efficacy of BNT116 Alone and in Combinations in Patients With Advanced Non-small Cell Lung Cancer
  NCT05142189 · Phase: Phase 1 · Ages: 18 Years and older · Sex: All (male and female) · 45 locations
• EGFR-mutated Lung Cancer in Randomized Investigator-Initiated Study
  NCT06486142 · Phase: Phase 3 · Ages: 18 Years and older · Sex: All (male and female) · 1 location
• Neoadjuvant Osimertinib + Chemotherapy for EGFR-mutant Stage III NSCLC
  NCT05011487 · Phase: Phase 2 · Ages: 18 Years to 75 Years · Sex: All (male and female) · 1 location
• Phase II Study of Sacituzumab Tirumotecan in Combination With Osimertinib for Neoadjuvant Treatment in Patients With Resectable Epidermal Growth Factor Receptor (EGFR)-Mutated Non-Small Cell Lung Cancer
  NCT07329322 · Phase: Phase 2 · Ages: 18 Years to 75 Years · Sex: All (male and female) · 1 location
• Phase III, Open-label Study of First-line Osimertinib With or Without Datopotamab Deruxtecan for EGFRm Locally Advanced or Metastatic Non-small Cell Lung Cancer
  NCT06350097 · Phase: Phase 3 · Ages: 18 Years and older · Sex: All (male and female) · 167 locations
• Prospective Non-Interventional Study Comparing Osimertinib +/- Chemotherapy for EGFR-Mutated NSCLC Patients
  NCT06538038 · Phase: Not specified · Ages: 18 Years and older · Sex: All (male and female) · 146 locations
• Study of Oral EGFR Inhibitor DZD6008 Combined With Sunvozertinib in Patients Who Have Advanced NSCLC With EGFR Mutations (TIAN-SHAN8)
  NCT07079475 · Phase: Phase 1, Phase 2 · Ages: 18 Years and older · Sex: All (male and female) · 16 locations
• Study of Osimertinib With Carotuximab in Advanced, EGFR-mutated Non-Small Cell Lung Cancer
  NCT05401110 · Phase: Phase 1 · Ages: 18 Years and older · Sex: All (male and female) · 5 locations
• Treatment Strategies and Survival Outcome for Non-small Cell Lung Cancer With Oncogenic Mutation
  NCT04322890 · Phase: Phase 2 · Ages: 18 Years and older · Sex: All (male and female) · 1 location
• Vebreltinib Plus PLB1004 as the First-line Therapy for Patients With EGFRm+/MET+ Locally Advanced or Metastatic NSCLC.
  NCT06574347 · Phase: Phase 2 · Ages: 18 Years and older · Sex: All (male and female) · 1 location

Common questions

How many trials study Osimertinib for Non-Small-Cell Lung Cancer?

16 recruiting trials.

Is this list complete?

No. For the full record, search ClinicalTrials.gov.